Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F. Grossmann(University of Utah), Antoni Ribas(University of California, Los Angeles), John M. Kirkwood(UPMC Hillman Cancer Center), Karl D. Lewis(University of Colorado Denver), Ragini R. Kudchadkar, Michael V. Knopp(University of California, Los Angeles), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Elad Sharon(National Cancer Institute), Douglas B. Johnson(Vanderbilt University Medical Center), Zeynep Eroglu(Moffitt Cancer Center), Megan Othus(Cancer Research And Biostatistics), Sapna P. Patel(JSS Dental College and Hospital), Larissa A. Korde(National Cancer Institute), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bartosz Chmielowski(UCLA Health), Kari Kendra(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Justine V. Cohen(Massachusetts General Hospital), Pauline Funchain(Palo Alto University), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Vernon K. Sondak(Advanced Dermatology), Elizabeth I. Buchbinder(Massachusetts General Hospital), Robert M. Conry(University of Alabama), Krishna S. Gunturu, Sama Ahsan(Johns Hopkins Hospital), Thach‐Giao Truong, Brian Gastman(Cleveland Clinic), Hongli Li(Shanghai University of Traditional Chinese Medicine), Magdalena Kovacsovics-Bankowski, James Moon(University of Michigan), Teresa M. Petrella, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k